2025张江药谷产业生态全球推介会在上海举行

Core Insights - The 2025 Zhangjiang Pharmaceutical Valley Global Promotion Conference and International Innovation Conference was held in Shanghai, emphasizing the importance of the biopharmaceutical industry as a key sector in Shanghai's economic development [1] Group 1: Industry Development - The biopharmaceutical industry is one of Shanghai's three leading industries and a focal point for the new round of technological revolution and competition [1] - Pudong is striving to create a world-class biopharmaceutical industry cluster by enhancing innovation capabilities and promoting the emergence of "First-in-class," "First-in-China," and "First-in-Human" innovative products [1][2] - In the first half of this year, Pudong achieved a biopharmaceutical industry scale of 220 billion yuan, with an annual compound growth rate of 14% [3] Group 2: Policy and Strategic Initiatives - The Shanghai government is aligning with international standards to build a vibrant biopharmaceutical industry cluster, focusing on innovation as the driving force [2] - The State Council issued guidelines to enhance the innovation vitality and global competitiveness of China's pharmaceutical industry [2] - A comprehensive implementation plan for the high-end medical device industry in Pudong was announced, emphasizing "technology innovation + system innovation" as a dual driving force [4] Group 3: Innovation and Achievements - Zhangjiang Pharmaceutical Valley has approved 29 new Class I domestic drugs, with several innovative drugs set to launch in 2025, including the first humanized ultra-long-acting GLP-1 receptor agonist and the first gene therapy drug [4] - In the field of innovative medical devices, 38 innovative device products have been approved, with recent launches filling domestic technology gaps [4] - The establishment of the Pudong New Area Biopharmaceutical Industry Development Expert Committee aims to provide intellectual support for the construction of a world-class biopharmaceutical industry cluster [5]